Perspective Therapeutics Q3 2023 Earnings Report

Perspective Therapeutics EPS Results

• Actual EPS: -$0.40
• Consensus EPS: -$0.40
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Perspective Therapeutics Revenue Results

• Actual Revenue: $2.19 million
• Expected Revenue: $2.20 million
• Beat/Miss: Missed by -$10.00 thousand
• YoY Revenue Growth: N/A

Perspective Therapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/14/2023
• Time: N/A

Perspective Therapeutics (NYSE:CATX), together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.